Targeting the YY1-Bcl2-c-Myc Axis in the treatment of non-Hodgkin lymphoma
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · 2025
DOI: 10.1016/j.bbcan.2025.189395 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2025. Verfasst von Mai P Ho und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, Immunology & Molecular Genetics, David Geffen School of Medicine, Jonsson Comprehensive Cancer Center, University of Cali…. Hauptthemen laut MEDLINE: YY1 Transcription Factor, Proto-Oncogene Proteins c-myc, Proto-Oncogene Proteins c-bcl-2, Lymphoma, Non-Hodgkin. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 308 Literaturangaben.
Abstract (Originalsprache)
Non-Hodgkin lymphoma (NHL) presents a complex therapeutic challenge due to its heterogeneous nature and the high incidence of relapse following initial treatment. As such, patients who are more susceptible to treatment resistance face a poor prognosis with limited treatment options. With recent advances, the direct targeting of overexpressed gene products is a novel therapeutic approach to overcome resistance mechanisms in unresponsive NHL patients. In the pathogenesis of NHL, we suspect aberrant deregulations amongst three major oncogenes: Yin Yang 1 (YY1), B-cell lymphoma 2 (Bcl-2), and Myelocytomatosis oncogene (c-Myc). Through analyses of the reported literature data, we have determined, indeed, multiple cross-talk signaling pathways (i.e. with factors MDM2, NF-κΒ, SENP1, TGF-β, p53, ERK) for YY1, Bcl-2, and c-Myc that enable malignant cells to evade immune surveillance, promote tumor aggressiveness, and maintain resistance against various treatment modalities. In addition, we also present various approaches and agents to target each of the gene products, with discussion of challenges faced to generate such agents that specifically target the tumor cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Microbiology, Immunology & Molecular Genetics, David Geffen School of Medicine, Jonsson Comprehensive Cancer Center, University of California at Los Angeles, CA 90095, USA. Electronic address: maiho123@ucl…
- Laboratory of Experimental Oncology, Division of Surgery, School of Medicine, University of Crete, 71003 Heraklion, Greece.
- Department of Microbiology, Immunology & Molecular Genetics, David Geffen School of Medicine, Jonsson Comprehensive Cancer Center, University of California at Los Angeles, CA 90095, USA. Electronic address: bbonavida@me…
Zitieren
APA
Ho, M. P., Skouradaki, E., Baritaki, S., Otumo, E., & Bonavida, B. (2025). Targeting the YY1-Bcl2-c-Myc Axis in the treatment of non-Hodgkin lymphoma. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. https://doi.org/10.1016/j.bbcan.2025.189395
Vancouver
Ho MP, Skouradaki E, Baritaki S, Otumo E, Bonavida B. Targeting the YY1-Bcl2-c-Myc Axis in the treatment of non-Hodgkin lymphoma. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2025. doi:10.1016/j.bbcan.2025.189395
BibTeX
@article{Ho2025,
author = {Ho, Mai P and Skouradaki, Evagelia and Baritaki, Stavroula and Otumo, Etini and Bonavida, Benjamin},
title = {Targeting the YY1-Bcl2-c-Myc Axis in the treatment of non-Hodgkin lymphoma},
journal = {Biochimica et Biophysica Acta (BBA) - Reviews on Cancer},
year = {2025},
doi = {10.1016/j.bbcan.2025.189395}
}
EUVIMED